Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine
Matthieu Mahévas, Sylvain Audia, Victoire de Lastours, MARC F. MICHEL, Bernard Bonotte, Bertrand Godeau
Abstract
Open-access reader
Matthieu Mahévas, Sylvain Audia, Victoire de Lastours, MARC F. MICHEL, Bernard Bonotte, Bertrand Godeau
Abstract
Open-access reader
Felty’s syndrome (FS) is a rare disease defined by the presence of 3 conditions: rheumatoid arthritis (RA), neutropenia, and splenomegaly 1. It has been subdivided into two entities, depending on the presence or absence of large granular lymphocyte (LGL) leukaemia. LGL leukaemia is diagnosed by
OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Felty’s syndrome (FS) is a rare disease defined by the presence of 3 conditions: rheumatoid arthritis (RA), neutropenia, and splenomegaly 1. It has been subdivided into two entities, depending on the presence or absence of large granular lymphocyte (LGL) leukaemia. LGL leukaemia is diagnosed by
Key concepts: Felty's syndrome, Neutropenia, Medicine, Hydroxychloroquine, Rheumatoid arthritis, Arthritis, Leukopenia, Dermatology